Abata Therapeutics

Chengdu Boaovax Biotechnology, founded in November 2015, is focused on R & D of vaccines

宜明昂科2015年6月成立于上海张江，自创立以来，坚持全球创新和自主研发，围绕着固有免疫和获得性免疫多个潜力靶点做出了一系列产品布局。迄今为止，已在中国获得9个临床批件，在美国获得2个临床批件。另外，IMM01与PD-1针对多个实体瘤适应症的联合用药临床试验申请已获药监局受理。现有临床数据表明，无论安全性还是有效性，IMM01在全球范围靶向CD47的分子中表现亮眼，有很大希望成为同类最优（Best-In-Class）产品。同时，公司围绕CD47靶点布局的一系列联合用药和双抗，能够更大的拓展CD47靶点实体瘤适应症潜力。CD47之余，宜明昂科围绕固有免疫和获得性免疫进一步拓展布局了后续两个具有全球竞争力的创新潜力靶点，固有免疫和获得性免疫靶点形成强大协同，成为推动公司不断创新发展的强有力的引擎。

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.In March 2023, ONL Therapeutics LLC closed on the first tranche of a $15 million Series C Preferred Stock financing round.In December 2020 ,ONL Therapeutics announced that it closed on $46.9 million in a Series B Preferred Stock financing round. In January 2022, ONL Therapeutics Inc closed on its second tranche of Series B financing raising $46.9 million.In August 2019, the company raised US $3 million in a convertible note financing.In May 2017, the company closed a US $4.25 million Series A round of fundraising